Identification of Gene Expression Signature for Panitumumab Sensitivity in Untreated Locally Advanced SCCHN
Status:
Terminated
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to identify which cancer-related genes are turned on or turned
off in order to determine how well a patient will respond to the study drug, panitumumab.
Panitumumab was added to standard adjuvant or primary radiation therapy. There were subjects
that receive surgery followed by therapy and subjects that receive radiation therapy without
surgery.
Subjects entering this study had locally advanced disease that can be treated with surgery
and/or radiation therapy. Fresh frozen tumor tissue were available for genomics analysis
prior to initiating panitumumab therapy. If fresh frozen tissue was not available at time of
consent, a biopsy was required to participate in this trial.